Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) generates frequent news as a medical technology company focused on obstructive sleep apnea (OSA), snoring and other sleep-related breathing disorders. News about Vivos often centers on its FDA-cleared oral appliance technologies, clinical data releases, acquisitions of sleep centers and collaborations with medical practices that adopt its treatment methods.
Readers following VVOS news can expect regular updates on the company’s Complete Airway Repositioning and/or Expansion (CARE) devices, including the DNA appliance for pediatric OSA and other oral appliances in its portfolio. Vivos has announced multicenter clinical trial results, additional clinical datasets and peer-reviewed publications that it says support the safety and efficacy of its devices in both children and adults. These clinical milestones are a recurring theme in the company’s press releases.
Vivos also issues news about its business model and operations, such as the acquisition of The Sleep Center of Nevada and the rollout of an updated sleep practice affiliation model with partners like MISleep Solutions in Auburn Hills, Michigan. These items describe how Vivos integrates its diagnostic tools and therapies into sleep testing and treatment centers, and how it deploys Sleep Optimization teams to manage patient demand.
In addition, VVOS news includes financial results, conference call announcements, Medicare and CMS PDAC developments related to devices like the VidaSleep oral appliance, and participation in investor or research-focused events. For investors and observers interested in the intersection of sleep medicine, medical devices and healthcare services, the VVOS news feed offers ongoing insight into how Vivos is applying its technologies and partnerships in the OSA treatment landscape.
Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration with SoundHealth to distribute SoundHealth’s FDA-cleared Sonu® Band and new Spatial Sleep™ band across Vivos’ clinical network. Vivos will resell the devices and gain access to SoundHealth’s CT-accurate smartphone facial scanning and voice biomarker technology to aid screening, treatment, and monitoring of airway and sleep disorders.
The partnership leverages Vivos’ network of over 2,000 Vivos-trained dentists and sleep providers and aims to expand access to personalized, non-drug airway and sleep therapies.
Vivos Therapeutics (Nasdaq: VVOS) closed the exercise of outstanding warrants and received approximately $4.64 million in gross proceeds on January 20, 2026. The exercised warrants covered an aggregate of 1,982,356 originally issued in 2023–2024 at reduced exercise prices of $2.34 per share. As consideration, the company issued private new unregistered warrants to purchase 3,964,712 shares at $2.09 per share with staggered expirations (24 months and five years). Shares issuable on the exercised warrants are registered on Form S-3; new warrants were offered via an exemption and resale registration will be filed. Proceeds are intended for working capital and general corporate purposes.
Vivos Therapeutics (Nasdaq: VVOS) announced a definitive agreement for immediate exercise of outstanding warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices of $3.83–$5.05. The shares issuable upon exercise are registered for resale on Form S-3. Gross proceeds to the company are expected to be approximately $4.64 million before placement agent fees and offering expenses. The company will issue private, unregistered new warrants to purchase up to 3,964,712 shares at $2.09 per share; portions expire in 24 months and five years. The offering is expected to close on or about January 20, 2026, and net proceeds will be used for working capital and general corporate purposes.
Vivos Therapeutics (NASDAQ: VVOS) opened an affiliated sleep testing and treatment center in Auburn Hills, Michigan on Dec. 16, 2025, expanding its commercial affiliation model beyond Las Vegas.
The center operates under a July agreement with MISleep Solutions, where Vivos built out the facility, staffed and trained personnel, and will provide its FDA-cleared diagnostic and therapeutic products for obstructive sleep apnea (OSA). Vivos positions the affiliation model as capital-efficient versus outright acquisitions while preserving accretive economics and expects to pursue similar partnerships nationwide.
Vivos Therapeutics (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will join a Water Tower Research fireside chat on December 16, 2025 at 11:00 am ET.
Management will discuss the company’s strategic business model pivot, operational execution, the market opportunity and competitive environment for sleep-related breathing disorder treatments, and Vivos’ growth and financial strategies. The event is listen-only and requires registration. A replay will be available for 30 days in the Investor Relations section at vivos.com.
Vivos Therapeutics (NASDAQ: VVOS) reported strong third-quarter 2025 results driven by its June 2025 acquisition of The Sleep Center of Nevada (SCN). Q3 revenue was $6.8M, up 78% sequentially and 76% year-over-year, and nine-month revenue was $13.6M. SCN contributed $2.2M in diagnostic testing and $1.3M in treatment center revenue in Q3. Gross profit for Q3 was $3.9M with gross margin at 58%. Operating expenses rose to $8.7M in Q3, producing an operating loss of $4.7M. At September 30, 2025, cash was $3.1M and stockholders' equity was $2.5M. Management will host a conference call on Nov 19, 2025 at 5:00 pm ET.
Vivos Therapeutics (NASDAQ: VVOS) will release its third quarter 2025 financial results after market close on Wednesday, November 19, 2025. The company will host a conference call and webcast at 5:00 pm Eastern on November 19, 2025 to review results and provide operational updates, including discussion of strategic collaborations and their anticipated effect on near-term revenue growth and cash burn. A replay will be available through December 3, 2025, and the webcast archive will remain on the company website for 30 days.
Vivos Therapeutics (NASDAQ:VVOS) has released new clinical data demonstrating significant improvements in children with ADHD and OSA using their FDA-cleared Daytime-Nighttime Appliance (DNA). The study showed remarkable results, including a 50% decrease in pediatric sleep issues and a 58% decrease in ADHD symptoms.
The clinical trial, involving 48 children with an average age of 10.6 years, demonstrated 100% of patients experienced increased transpalatal width (+13.6%) and airway volume (+40%), while OSA severity decreased by 51.4%. The DNA appliance represents the only FDA-cleared non-surgical, non-pharmaceutical treatment for moderate to severe pediatric OSA in children ages 6-17.
The majority of improvements occurred within the first six months of treatment, offering a promising alternative to traditional adenotonsillectomy surgery and pharmaceutical interventions.Vivos Therapeutics (NASDAQ: VVOS) announced groundbreaking results from a multicenter clinical trial for their DNA (Daytime-Nighttime Appliance®) device in treating pediatric obstructive sleep apnea (OSA). Published in the European Journal of Pediatrics, the study demonstrated significant efficacy with 77% of participants achieving at least 50% reduction in OSA severity, and 93% improvement rate in severe cases.
The trial revealed an average 67.8% increase in airway volume and 17% complete OSA resolution. This non-surgical alternative challenges the current standard adenotonsillectomy surgery, which is only effective in 20-40% of cases. The DNA appliance, part of Vivos' C.A.R.E. line, addresses a critical need as up to 20.4% of U.S. children suffer from OSA, with 90% remaining undiagnosed.
Vivos Therapeutics (NASDAQ:VVOS), a medical device company focused on sleep-related breathing disorders, reported Q2 2025 financial results marked by a strategic pivot in their business model. The company completed the acquisition of The Sleep Center of Nevada (SCN), generating approximately $500,000 in diagnostic sleep testing revenue in just 20 days.
Q2 2025 financial highlights include revenue of $3.8 million (down from $4.1M in Q2 2024), gross profit of $2.1 million with a 55% margin, and increased operating expenses of $7.0 million. The company ended the quarter with $4.4 million in cash. Additionally, Vivos entered into its first management agreement with MISleep Solutions LLC in Michigan, demonstrating progress in their updated sleep practice management model.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
